GlassScriptPhysician profile
Kedar A Gokhale
NPI 1437134061
$2,145.54
in general payments reported to CMS, 2019-2025
32 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $56.15 · 2021: $344 · 2022: $412 · 2023: $136 · 2024: $269 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $567.20 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $189.13 | 2022-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $154.28 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $138.75 | 2019-2025 | Mounjaro, Zepbound |
| Smith+Nephew, INC. | $118.15 | 2021 | |
| Janssen Biotech, INC. | $116.59 | 2019-2025 | Tremfya |
| Abbvie INC. | $107.10 | 2019-2023 | |
| Asensus Surgical, INC. | $63.84 | 2022 | |
| Amarin Pharma, INC. | $55.38 | 2019-2022 | |
| Daiichi Sankyo INC. | $48.62 | 2025 | Injectafer |
| Pfizer INC. | $46.34 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $41.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.36 | 2019-2022 | |
| Kyowa Kirin, INC. | $38.22 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $38.15 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $35.61 | 2025 | Rezdiffra |
| Ardelyx, INC. | $35.44 | 2022-2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $34.10 | 2024-2025 | Voquezna |
| Medtronic, INC. | $32.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.85 | 2022-2023 | Xifaxan, Plenvu |
| Biocon Biologics INC | $20.14 | 2025 | Yesintek |
| Boston Scientific Corporation | $19.09 | 2019 | |
| Sandoz INC. | $18.50 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.48 | 2020 | |
| Sanofi Pasteur INC. | $14.62 | 2019 | |
| Zyla Life Sciences, INC. | $14.45 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.10 | 2024 | |
| 180 Medical, INC. | $13.93 | 2019 | |
| Endo Pharmaceuticals INC. | $13.61 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kedar Gokhale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.